Departments of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Peking University, Beijing, China.
APMIS. 2024 Jun;132(6):375-381. doi: 10.1111/apm.13402. Epub 2024 Mar 11.
In brain metastases, radiation necrosis (RN) is a complication that arises after single or multiple fractionated stereotactic radiosurgery (SRS/FSRS), which is challenging to distinguish from local recurrence (LR). Studies have shown increased RN incidence rates in non-small cell lung cancer (NSCLC) patients with oncogenic driver mutations (ODMs) or receiving tyrosine kinase inhibitors (TKIs). This study investigated enlarging brain lesions following SRS/FSRS, for which additional surgeries were performed to distinguish between RN and LR. We investigated seven NSCLC patients with ODMs undergoing SRS/FSRS for BM and undergoing surgery for suspicion of LR on MRI imaging. Descriptive statistics were performed. Among the seven patients, six were EGFR+, while one was ALK+. The median irradiation dose was 30 Gy (range, 20-35 Gy). The median time to develop RN after SRS/FSRS was 11.1 months (range: 6.3-31.2 months). Moreover, gradually enlarging lesions were found in all patients after 6 months post-SRS/FSR. Brain radiation necrosis was pathologically confirmed in all the patients. RN should be suspected in NSCLC patients when lesions keep enlarging after 6 months post-SRS/FSRS, especially for patients with ODMs and receiving TKIs. Further, this case series indicates that further dose reduction might be necessary to avoid RN for such patients.
在脑转移瘤中,放射性坏死(RN)是一种在单次或多次分割立体定向放射外科(SRS/FSRS)后出现的并发症,难以与局部复发(LR)相区分。研究表明,具有致癌驱动突变(ODMs)或接受酪氨酸激酶抑制剂(TKIs)的非小细胞肺癌(NSCLC)患者的 RN 发生率增加。本研究调查了 SRS/FSRS 后脑内病变扩大的情况,对这些病变进行了额外的手术以区分 RN 和 LR。我们调查了 7 名 NSCLC 患者,这些患者患有 ODM 并接受 SRS/FSRS 治疗 BM,并因 MRI 成像怀疑 LR 而行手术治疗。进行了描述性统计分析。在这 7 名患者中,6 名为 EGFR+,1 名为 ALK+。中位照射剂量为 30Gy(范围 20-35Gy)。SRS/FSRS 后发生 RN 的中位时间为 11.1 个月(范围 6.3-31.2 个月)。此外,所有患者在 SRS/FSRS 后 6 个月后均发现病变逐渐增大。所有患者的 RN 均经病理证实。对于 SRS/FSRS 后 6 个月后病变持续增大的 NSCLC 患者,应怀疑为 RN,尤其是 ODM 患者和接受 TKI 治疗的患者。此外,本病例系列表明,对于此类患者,可能需要进一步降低剂量以避免 RN。